These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 19964269)

  • 21. Antiarrhythmic and nonantiarrhythmic drugs for sudden cardiac death prevention.
    Das MK; Zipes DP
    J Cardiovasc Pharmacol; 2010 May; 55(5):438-49. PubMed ID: 20509177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. What happens when cardiac Na channel function is compromised? 2. Numerical studies of the vulnerable period in tissue altered by drugs.
    Starmer CF; Grant AO; Colatsky TJ
    Cardiovasc Res; 2003 Mar; 57(4):1062-71. PubMed ID: 12650884
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drugs to prevent sudden cardiac death.
    Erath JW; Hohnloser SH
    Int J Cardiol; 2017 Jun; 237():22-24. PubMed ID: 28341373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of antiarrhythmic therapy in patients at risk for sudden cardiac death: an evidence-based review.
    Hilleman DE; Bauman AL
    Pharmacotherapy; 2001 May; 21(5):556-75. PubMed ID: 11349745
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias.
    Belardinelli L; Liu G; Smith-Maxwell C; Wang WQ; El-Bizri N; Hirakawa R; Karpinski S; Li CH; Hu L; Li XJ; Crumb W; Wu L; Koltun D; Zablocki J; Yao L; Dhalla AK; Rajamani S; Shryock JC
    J Pharmacol Exp Ther; 2013 Jan; 344(1):23-32. PubMed ID: 23010360
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Na(+) and K(+) channel blockade on vulnerability to and termination of fibrillation in simulated normal cardiac tissue.
    Qu Z; Weiss JN
    Am J Physiol Heart Circ Physiol; 2005 Oct; 289(4):H1692-701. PubMed ID: 15937096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anisotropic effects of sodium channel blockers on the wavelength for ventricular excitation in dogs.
    Watanabe T; Yamaki M; Tachibana H; Yamauchi S; Kubota I; Tomoike H
    Jpn Circ J; 2000 Sep; 64(9):689-94. PubMed ID: 10981854
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New directions in the development of antiarrhythmic drugs.
    Miura DS; Rosen MR
    J Clin Pharmacol; 1984 Jul; 24(7):333-41. PubMed ID: 6090508
    [TBL] [Abstract][Full Text] [Related]  

  • 29. On the mechanism of action of antiarrhythmic agents.
    Grant AO
    Am Heart J; 1992 Apr; 123(4 Pt 2):1130-6. PubMed ID: 1313200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological and toxicological activity of RSD921, a novel sodium channel blocker.
    Walker MJA; Hayes ES; Saint DA; Adaikan G; Abraham S; Goldin AL; Beatch GN; MacLeod BA; Wall RA; Pugsley MK
    Biomed Pharmacother; 2018 Oct; 106():510-522. PubMed ID: 29990839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Basic cardiac electrophysiology and mechanisms of antiarrhythmic agents.
    Perry RS; Illsley SS
    Am J Hosp Pharm; 1986 Apr; 43(4):957-74. PubMed ID: 2871752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [New aspects of the molecular effect of anti-arrhythmia agents].
    Honerjäger P
    Herz; 1990 Apr; 15(2):70-8. PubMed ID: 2160907
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beta-blockers as antiarrhythmic agents.
    Zicha S; Tsuji Y; Shiroshita-Takeshita A; Nattel S
    Handb Exp Pharmacol; 2006; (171):235-66. PubMed ID: 16610347
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ranolazine in Cardiac Arrhythmia.
    Saad M; Mahmoud A; Elgendy IY; Richard Conti C
    Clin Cardiol; 2016 Mar; 39(3):170-8. PubMed ID: 26459200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ionic mechanisms of ischemia-related ventricular arrhythmias.
    Ducceschi V; Di Micco G; Sarubbi B; Russo B; Santangelo L; Iacono A
    Clin Cardiol; 1996 Apr; 19(4):325-31. PubMed ID: 8706374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. From pulsus to pulseless: the saga of cardiac alternans.
    Weiss JN; Karma A; Shiferaw Y; Chen PS; Garfinkel A; Qu Z
    Circ Res; 2006 May; 98(10):1244-53. PubMed ID: 16728670
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Indeterminacy of spatiotemporal cardiac alternans.
    Zhao X
    Phys Rev E Stat Nonlin Soft Matter Phys; 2008 Jul; 78(1 Pt 1):011902. PubMed ID: 18763977
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms of sudden cardiac death: oxidants and metabolism.
    Yang KC; Kyle JW; Makielski JC; Dudley SC
    Circ Res; 2015 Jun; 116(12):1937-55. PubMed ID: 26044249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alternans and the influence of ionic channel modifications: Cardiac three-dimensional simulations and one-dimensional numerical bifurcation analysis.
    Bauer S; Röder G; Bär M
    Chaos; 2007 Mar; 17(1):015104. PubMed ID: 17411261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sodium channel-blocking properties of spiradoline, a kappa receptor agonist, are responsible for its antiarrhythmic action in the rat.
    Pugsley MK; Saint DA; Hayes ES; Kramer D; Walker MJ
    J Cardiovasc Pharmacol; 1998 Dec; 32(6):863-74. PubMed ID: 9869491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.